A Takeda-backed GI and pain biotech quietly shutters

Kyle LaHucik

Senior Reporter

A biotech aiming to treat various gastrointestinal ailments, as well as develop a non-opiate pain med, quietly shut down last year after failing to find …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A Takeda-backed GI and pain biotech quietly shutters

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Sofinnova outlines $550M fund after IPOs and M&A deals

Exclusive: Florida cancer biotech raises $100M Series A

A Take­da-backed GI and pain biotech qui­et­ly shut­ters

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A Takeda-backed GI and pain biotech quietly shutters

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Sofinnova outlines $550M fund after IPOs and M&A deals

Exclusive: Florida cancer biotech raises $100M Series A